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Abstract
For more than four decades the cause of most type A influenza virus infections of humans has been attributed to only two
viral subtypes, A/H1N1 or A/H3N2. In contrast, avian and other vertebrate species are a reservoir of type A influenza virus
genome diversity, hosting strains representing at least 120 of 144 combinations of 16 viral hemagglutinin and 9 viral
neuraminidase subtypes. Viral genome segment reassortments and mutations emerging within this reservoir may spawn
new influenza virus strains as imminent epidemic or pandemic threats to human health and poultry production. Traditional
methods to detect and differentiate influenza virus subtypes are either time-consuming and labor-intensive (culture-based)
or remarkably insensitive (antibody-based). Molecular diagnostic assays based upon reverse transcriptase-polymerase chain
reaction (RT-PCR) have short assay cycle time, and high analytical sensitivity and specificity. However, none of these
diagnostic tests determine viral gene nucleotide sequences to distinguish strains and variants of a detected pathogen from
one specimen to the next. Decision-quality, strain- and variant-specific pathogen gene sequence information may be critical
for public health, infection control, surveillance, epidemiology, or medical/veterinary treatment planning. The Resequencing
Pathogen Microarray (RPM-Flu) is a robust, highly multiplexed and target gene sequencing-based alternative to both
traditional culture- or biomarker-based diagnostic tests. RPM-Flu is a single, simultaneous differential diagnostic assay for all
subtype combinations of type A influenza viruses and for 30 other viral and bacterial pathogens that may cause influenza-
like illness. These other pathogen targets of RPM-Flu may co-infect and compound the morbidity and/or mortality of
patients with influenza. The informative specificity of a single RPM-Flu test represents specimen-specific viral gene
sequences as determinants of virus type, A/HN subtype, virulence, host-range, and resistance to antiviral agents.
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Introduction
There are sixteen recognized serological subtypes of type A
influenza virus hemagglutinin (H1 through H16) and 9 type A
neuraminidase subtypes (N1 through N9). Among the combina-
torial diversity of 144 possible A/HN subtypes, relatively few
subtypes have been identified as causes of human disease. Four
pandemic outbreaks in the last century, one catastrophic, appear
to have introduced the subsequently prevalent seasonal human
influenza virus subtypes A/H1N1 (Spanish flu, 1918), A/H2N2
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again (Swine flu, 1976; Russian flu, 1977). The current year 2009
has been marked by a late season pandemic-scale emergence of a
novel A/H1N1 outbreak strain, raising immediate concerns for
public health as well as for pork and poultry production industries
worldwide.
As with the few common subtypes of human type A influenza
viruses, there are similarly few subtypes of type A influenza viruses
that are associated with most influenza infections of swine, horses
or dogs. In distinct contrast, wildfowl species are natural hosts and
a global reservoir for the majority of possible influenza A/HN
subtypes. Many of these variant strains appear to be associated
with endemic infections, often asymptomatic in avian hosts [1].
Incidental infections of humans by avian influenza viruses have
been documented for avian influenza subtypes A/H5N1, A/
H7N2, A/H7N3, A/H7N7, A/H9N2, A/H10N7 and A/H11N9.
Recent outbreaks of ‘‘bird flu’’ may foreshadow an eventual
pandemic outbreak, in the emergence of strains and variants with
enhanced pathogenicity, virulence and transmissibility in human
hosts. Examples of such outbreaks include A/H5N1 Hong Kong,
1997; H9N2 Hong Kong, 1999; A/H7N7 Netherlands, 2003; A/
H5N1 Southeast Asia, 2004. Some avian A/H5 and A/H7 strains
of influenza virus are recognized as highly pathogenic (HP) in
domestic poultry and concerns arise that this phenotype may carry
over to infections of humans. Since 1997, human infections
associated with the Eurasian-African lineage of A/H5N1 HP avian
influenza virus have been associated with 467 documented cases in
15 countries with high mortality (282 deaths) [2; updated 30
December 2009].
Fortunately, infectious transmission of such avian influenza
virus strains between humans continues to be limited. However,
history suggests that further evolution of these or other type A
influenza strains could emerge as a next pandemic strain.
Similarly, variant type A influenza virus strains have emerged
from time to time, imposing serious costs and burdens upon
poultry and livestock production.
Because the natural history and the molecular biology of
influenza viruses reflect such viral genome diversity, there is a
critical need for rapid, sensitive, specific, and informative assays to
detect and characterize any subtype of influenza virus. Benchmark
standard methods that employ propagation of virus in cell culture
or in embryonating chicken eggs, with assays using panels of
specific serological reagents, or reverse transcriptase polymerase
chain reaction (RT-PCR)-based assays, using panels of short
oligonucleotide primers and probes, are either slow and time
consuming, or expensive. As prevailing strains of avian influenza
continue to evolve and diverge, diagnostic assays that are based
only on specific recognition of short signature sequences or peptide
biomarker loci will increasingly fail, through false-positive and/or
false-negative results. This will adversely impact critical decision-
making.
This report describes a re-sequencing pathogen microarray
(RPM)-based assay for simultaneous detection, identification and
characterization of any subtype of type A human or avian
influenza virus, based on rapid, sensitive and specimen-specific
determination of nucleotide sequences from viral hemagglutinin,
neuraminidase, and other genes.
Methods
Ethics Statement
All specimens described in this report that were originally
obtained from human subjects were obtained with informed
(verbal) consent of study participants allowing for further research
use, following Institutional Review Board-approved research
protocol NHRC.1999.0002, Triservice Population-Based Surveil-
lance for Respiratory Pathogens Among High-Risk Military
Personnel, CAPT Kevin Russell, MC, Principal Investigator.
The NHRC IRB approved verbal consent for this protocol
because of minimal risk to volunteers. Samples are collected for
accredited diagnostic testing, and only used for further research in
a de-identified manner with minimal demographic data (date and
site of collection, age, sex), tested only for respiratory pathogens
and analyzed in aggregate, and resulting data is not used for
patient treatment or management. No part of this study was
conducted as experimentation involving live vertebrate animals.
Reference strains of avian influenza viruses were propagated in
laboratory cultures for analysis of viral RNA.
Specimen Collection and Sample Processing
The Naval Health Research Center (NHRC) collects, analyzes,
and archives throat-swab specimens from human subjects as part
of respiratory infection surveillance at US basic military training
facilities. Research use of donated specimens is permitted under
the local Institutional Review Board’s approved protocol-compli-
ant informed consent (see Acknowledgments). Throat swabs are
suspended in stabilizing transport media and archived frozen at
280uC. Viral culture and PCR-based testing protocols are used at
the NHRC diagnostic laboratory to determine the presence or
absence of influenza virus, and these assays are accredited by the
College of American Pathologists as compliant with the Clinical
Laboratory Improvement Amendments of 1988, and the Depart-
ment of Defense Clinical Laboratory Improvement Program of
1994.
Cloacal swabs and/or tracheal swabs from migratory birds
(mostly waterfowl) and commercial poultry; tracheal and lung
tissue samples from dead birds; human throat swabs and one
human lung sample from a deceased patient were collected by
Naval Medical Research Unit No. 3 (NAMRU-3, Cairo, Egypt).
Avian influenza viruses in these samples were cultured using
chicken eggs and/or Madin-Darby canine kidney cell cultures
(MDCK, American Type Culture Collection, CCL-34). Sample
collection and viral culture techniques were as described [3]. Total
RNA was extracted and purified from culture isolates, and 1:100
to 1:1000 dilutions were used for diagnostic evaluations. Aliquots
were forwarded from NHRC to the Naval Research Laboratory
(NRL, Washington, DC) for RPM-Flu assay (TessArray RPM-Flu
3.1 Kit (RPM-Flu), TessArae, LLC, Potomac Falls, VA).
The U.S. Department of Agriculture, Agriculture Research
Service (USDA-ARS) Southeast Poultry Research Laboratory
(SEPRL, Athens, GA) selected specimens from its reference strain
archive for blinded analysis by RPM-Flu. These samples
comprised 20 representative avian influenza A/HN strains and
also included 2 avian paramyxoviruses as controls. Total nucleic
acid extractions and purifications (MagNA Pure, Roche Applied
Science, Indianapolis, IN) were performed following harvest from
infected eggs at SEPRL. A 30 ml aliquot from the final preparation
was frozen and forwarded for RPM-Flu analysis.
Reference Control Templates
The NRL group evaluated pathogen detection and identifica-
tion capabilities of the RPM-Flu assay and kit components from
TessArae, using control nucleic acid templates in assays in lieu of
specimen total nucleic acid. Sources of control nucleic acid
templates included type cultures of reference strain Eurasian-
African A/H5N1 high pathogenicity influenza virus obtained from
the Centers for Disease Control and Prevention (Atlanta, GA).
Reference control templates as mixtures of the A/H1N1, A/
Influenza Virus Identification
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preparations (Influenza Virus Vaccine Live, Intranasal, FluMist,
2004–2005 Formula; MedImmune Inc., Gaithersburg, MD), or
from inactivated virus preparations (Influenza Virus Vaccine
[Fluvirin] Purified Surface Antigen Vaccine, 2006–2007 Formula,
Package Insert; Chiron Corporation/Novartis Vaccines and
Diagnostics, Inc., Emeryville, CA). Synthetic DNA preparations
were purchased from Blue Heron Biotechnology (Bothell, WA) as
templates to represent other type A influenza hemagglutinin (H2,
and H4 through H16) and neuraminidase (N3 through N9) gene
sequences, as well as other pathogen gene sequences that are used
as detectors on the RPM-Flu array. In some cases, the NRL group
outsourced (Macrogen USA, Gaithersburg, MD) corroborative de
novo gene sequence determinations from amplified products from
hemagglutinin (HA), matrix (M), neuraminidase (NA), non-
structural (NS1) and RNA-dependent RNA polymerase subunit
(PB2) genes.
RPM-Flu Assay
Figure 1 illustrates the pathogen gene re-sequencing capacity of
the RPM-Flu assay as both complementary strands of 117,254 bp
of gene sequences, distributed across 188 detector tiles, represent-
ing 30 different categories of viral and bacterial respiratory
pathogens. The 30 other types of viruses and bacterial targeted by
the RPM-Flu assay as agents of flu-like illness are identified in
Supplemental Information Figure S1. A single total nucleic acid
preparation from a single aliquot of a single specimen is
simultaneously assayed for possible detection and illumination of
specimen-specific gene sequences from each of the 188 indepen-
dent target pathogen gene sequencing detector tiles on the
array.
The largest segment of the RPM-Flu microarray (41,063 bp) is
allocated to 40 detector tiles to represent the multiple subtypes of
type A and type B HA and NA genes, selected type A M genes,
and conserved NS and PB2 gene sequences from avian influenza
virus A/H5N1.
Selected specimens were thawed to retrieve aliquots for
extraction and purification of total nucleic acid for multiple
assays, including RPM-Flu testing. Each RPM-Flu assay con-
sumed about 30 ml (2%) of the originally archived specimen (about
1.5 ml). RPM-Flu analysis of specimen total nucleic acid followed
the manufacturer’s recommendations (TessArae, LLC; protocol
details are provided with the RPM-Flu 3.1 Kit User Manual and
are available online at www.tessarae.com).
The RPM-Flu assay protocol is executed as a series of specimen
and sample processing steps, listed below and indicating
approximate time required for each step:
1. Extraction of total nucleic acid; reverse transcription to convert
target RNA sequences to cDNA – 1 hour
2. Multiplexed amplification of targeted gene sequences by
thermal cycling – 2.5 hour
3. Pooling, purification and fragmentation of amplification
products – 0.5 hour
4. End-labeling (biotinylation) of amplification products –
0.5 hour
5. Hybridization of labeled products to microarrays – 4 hour to
16 hour (overnight preferred)
6. Washing and staining arrays – 1.5 hour
7. Scanning arrays for data acquisition – 0.15 hour
The abbreviated 4-hour hybridization time (5. above) reduces
assay cycle time to single day, which may be helpful if same-day
test results are a critical consideration. The overnight (,16 hour)
hybridization time is recommended and preferred to optimize
Figure 1. Influenza virus gene targets of the RPM-Flu assay. The TessArray RPM-Flu 3.1 allocates 40 detector tiles (41,063 bp) that represent
influenza virus hemagglutinin genes (16 type A and 1 type B) and neuraminidase genes (9 type A and 1 type B), matrix genes (3 type A and 1 type B),
and also the conserved NS and PB2 genes of avian influenza virus strain A/H5N1. The remaining 76,191 bp of re-sequencing capability on the
microarray (as large red wedge) are distributed among 2 control detector tiles and 142 detector tiles that represent genes of other pathogens that
may cause ‘‘flu-like’’ respiratory illness in humans. These other pathogens include viruses (adenovirus, enterovirus and rhinovirus, coronavirus,
herpesvirus, measles virus, metapneumovirus, parainfluenzavirus, respiratory syncytial virus, rubella virus, and poxvirus [variola]) and bacteria (Bacillus
[anthracis], Bordetella, Chlamydophila and Chlamydia, Corynebacterium, Francisella, Haemophilus, Klebsiella, Legionella, Moraxella, Mycobacterium,
Mycoplasma, Neisseria, Pseudomonas, Streptococcus, Staphylococcus and Yersinia).
doi:10.1371/journal.pone.0008995.g001
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generated gene sequences from detected target pathogens.
RPM-Flu Assay Data Analysis
Analysis of RPM-Flu assay data now differs from earlier
reported through the development of the prototype assay
platform RPMv1 [4,5]. Each RPM-Flu assay of a specimen
generates sequence data as base calls (A, G, C, or T) across each
detector tile of Affymetrix CustomSeq-formatted microarrays [6]
(see Affymetrix Technical Note, 2006, GeneChip CustomSeq
Resequencing Array Base Calling Algorithm Version 2.0:
Performance in Homozygous and Heterozygous SNP Detection).
Image data acquired from GeneChip Instrument System
scanning under GeneChip Operating Software control is
translated by GSEQ sequence analysis software (Affymetrix
Inc., Santa Clara, CA).
TessArray Sequence Analysis (TSEQ) software evaluates a ‘‘C3
Score’’ for each RPM-Flu detector tile, as a metric of detected
DNA sequence quantity and quality. The C3 Score is the total
number of GSEQ-identified nucleotides that appear in runs of
three or more consecutive (non-N) base calls, expressed as
percentage of the length (nucleotides) of each RPM-Flu detector
tile sequence. This approach to definition of a detected sequence
reduces background noise from spurious false-positive hybridiza-
tions of 25-base oligonucleotide probes that could lead to isolated
and relatively uninformative single base calls.
Relaxed and stringent target pathogen detection and reporting
thresholds for the RPM-Flu assay have been statistically and
empirically established for all of the resequencing detector tiles at
C3 Score .10 or C3 Score $20, respectively. RPM-Flu assay
results from hundreds of clinical and field specimens as well as
laboratory reference strains and synthetic DNA templates
(aggregate data not shown) have demonstrated that these detection
thresholds often represent C3 Scores that are more than 6
standard deviations (.6s, P,0.000003) above the mean of C3
Scores from thousands of detector tiles from assays performed in
the absence of positive control templates.
All sequences from an RPM-Flu assay that meet a detection and
reporting threshold are automatically subjected to alignment-
based search of the TessArray Validated Reference Sequence
Database (VRSD) (most recently validated instance 10 August
2009), using a dedicated server-based implementation of the Basic
Local Alignment Search Tool, BLAST, version 2.2.17 [7]. This
enables identification of one or several most similar (and
equivalently matching) sequence records for each target pathogen
gene sequence that may be generated in the assay of every
specimen. Adjustable parameters for the BLAST search are set as:
word size 11 (or 7 if C3 Score ,30), match/mismatch penalty
+1/21, gap costs as existence/extension +2/+1, low complexity
region filter off, and mask options off.
In order to qualify for reporting of target pathogen detection
using the relaxed threshold (C3 Score .10), a BLAST alignment
and sequence similarity search using the assay-generated sequence
of basecalls must return one or more most similar sequence
records from the search database (as TessArae’s VRSD) that are
concordant with the identity of the tentatively identified target
pathogen suggested by the identity of the particular resequencing
detector tile.
Viral Stocks for Determinations of Assay Sensitivity
Aliquots from two throat swab specimens collected during the
2008–2009 influenza were used for propagation of stocks by
infection of MDCK cell cultures.
A/California-NHRC/BRD10622N/2009(H1N1)
A/California-NHRC/BRD10601N/2009(H3N2)
Infected culture lysates were then diluted for infections of
replicate shell vial cultures to determine infectious titers (per-
formed by ViraPur, San Diego, CA). The resulting stocks of
BRD10622N(H1N1) and BRD10601(H3N2) were determined to
contain 3.16610
7 TCID50/ml and 1.78610
7 TCID50/ml,
respectively.
Serial ten-fold dilutions of viral stocks for RPM-Flu assays were
prepared using fresh cell culture media as diluent, from 10
0 (neat)
to 10
23, and then three-fold dilutions were prepared from 1:3,000
to 1:2,187,000. The routine RPM-Flu protocol for total nucleic
extraction and purification was performed on each of the triplicate
diluted samples of the viral stocks for identity-blinded triplicate
RPM-Flu assays.
Results
RPM-Flu Specificity: Analysis of Trivalent Influenza
Vaccine
The influenza virus subtype A/H1 gene detector tile
‘HA1(H1N1)’ on the RPM-Flu microarray is an array of 11,808
resequencing oligonucleotide probes (25-mers), representing the
nucleotides 113 through 1,588 of the A/New Caledonia/20/99
(H1N1) strain hemagglutinin gene (GenBank Accession Number
AY289929). This is the actual A/H1N1 strain of influenza virus
representing the viral HA1 gene product in the 2004–2005 vaccine
configuration.
An aliquot of FluMist vaccine (2004–2005) was subjected to
RPM-Flu assay, from which 1,351 specific base calls were
determined across the HA1(H1N1) detector tile, resulting in C3
Score=91.5. BLAST analysis returned AY289929 A/New
Caledonia/20/99 (H1N1) as the most similar sequence record
from alignment-based search across the entire GenBank, with
the limit (minimum) expectation value of 0.0 (or E-value=1.0e-
180).
Figure 2 shows the alignment of a 540-nucleotide segment of
this RPM-Flu assay detected sequence, below corresponding
intervals of the RPM-Flu detector tile sequence. This part of the
RPM-Flu HA1(H1N1) detector tile spans the locus of the A/H1
hemagglutinin peptide cleavage site [8]. Each of the nine
successive 60 bp RPM-Flu assay-detected HA1 sequence segments
shown in the inset was subjected to BLAST alignment and
similarity analysis. These short query sequences (60 bp) are
identical matches to corresponding hemagglutinin sequence
segments of many different A/H1N1 isolates, but in each case,
the list of identical sequence record(s) returned by BLAST includes
one or more A/New Caledonia/20/99 (H1N1) records. This
includes those 60 bp lines with runs of up to 12 uncalled bases (N).
With the exception of small gaps of uncalled bases, the detected
sequence is identical to the prototype sequence of the RPM-Flu
HA1(H1N1) detector tile.
This example of the integrity of RPM-Flu assay-generated
target pathogen gene sequencing for detection and identification is
reinforced by results for the other specific hemagglutinin,
neuraminidase, and matrix gene sequences from the same RPM-
Flu assay of the same aliquot of FluMist vaccine. Table 1 shows
that the most similar sequence records returned from BLAST
analysis of assay-generated HA1, NA1, HA3, NA2, M(H1N1),
M(H3N2) gene sequences, as well as type B HA, NA and M gene
sequences, all correctly correspond to the actual influenza virus
strains used to represent these components in the 2004–2005
vaccine configuration. This result is achieved even for instances
(HA3, NA2, B-HA, B-NA and both the type A and type B M
Influenza Virus Identification
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vaccine gene sequences do not precisely match. This reflects the
robust capability of the RPM-Flu resequencing microarray to
determine accurately the match or alternative mismatch of each
target gene nucleotide relative to corresponding nucleotide of the
detector sequence. These results also demonstrate the non-
interference of similar assay targets for RPM-Flu detection and
identification of multiple target gene sequences from the same
specimen.
Similarly specific typing, subtyping and strain identification
results to those shown in Table 1 have been obtained from
analyses of live and inactivated influenza vaccines configured for
the 2005–2006, 2006–2007 and 2009–2010 seasons (results
presented as SUPPLEMENTAL INFORMATION Tables S1,
S2, S3 and S4). We note that results of assays using inactivated
influenza virus vaccines identify detected type A matrix gene
sequences are most closely (and correctly) matched by matrix gene
sequence records from the A/Puerto Rico/8/34 (H1N1) master
donor strain that is used for gene segment re-assortment to select
for the inactivated vaccine strains.
The results in Table 1 are similar to those presented by Wang
et al. [9, that report’s Table 4]. That earlier work was performed
using the RPMv1 prototype precursor platform of the TessArray
RPM-Flu 3.1. The RPMv1 allocated only 7,691 base pairs (bp) to
9 different influenza-specific detector tiles, compared with the
RPM-Flu assay that allocates 41,063 bp over 40 influenza virus-
specific detector tiles (see Figure 1). The prototype RPMv1 assay
also employed random primers in a reverse transcription and
PCR-like protocol for total RNA amplification, and did not apply
the C3 quantity/quality metric methodology described in this
report for analysis of RPM-Flu assay-detected target pathogen
gene sequences.
RPM-Flu Specificity: Mutually Exclusive Detection and
Identification of Different Subtypes of Human and Avian
Influenza Viruses
Table 2 presents HA, NA and M gene detector tile C3 Scores
from RPM-Flu assays of samples representing prevalent human
subtypes A/H1N1, A/H3N2, and type B influenza viruses,
inactivated trivalent influenza virus vaccine, and selected A/HN
subtypes of type A avian influenza viruses. C3 Scores that failed to
meet or exceed the RPM-Flu assay detection and reporting
thresholds are shown in parentheses and in smaller font size to
Figure 2. RPM-Flu assay-generated sequences from analysis of tri-valent influenza virus vaccine. A 540-nucleotide segment of the
reported HA1 hemagglutinin sequence is shown aligned to the corresponding RPM-Flu HA1 gene detector tile sequence. This segment of the RPM-
Flu HA1(H1N1) detector tile spans the locus of the A/H1 hemagglutinin peptide cleavage site (red box).
doi:10.1371/journal.pone.0008995.g002
Influenza Virus Identification
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and identification of one or more of the RPM-Flu assay-targeted
influenza viruses.
Except for the vaccine sample, assays of each sample reported
sequences from only one hemagglutinin detector tile and one
neuraminidase detector tile, those corresponding precisely to the
specimen’s A/HN subtype or B type.
The mean values of C3 Scores from the positive detector tiles in
Table 2, and the background negative detector tiles, are
respectively
Mean C3pos=73.7624.0 (N=22)
Mean C3neg=3.262.3 (N=261)
[A six-sigma (6s) detection threshold for this data set is
C3=17.0]
The lowest positive control result from this data set was for the
NA gene of the NHRC-type B influenza virus-positive specimen
(C3pos=13.7). The same assay of this specimen generated higher
C3 Scores for sequences from the B-HA (C3=31) and B-M
(C3=34) detector tiles that exceeded the stringent detection
threshold. The type B-NA sequence from the assay met the
relaxed detection threshold (C3 Score .10), in part because
BLAST analysis of the sequence returned nine most similar type B
influenza virus NA gene sequence records. This corroborated a
tentative detection report (relaxed threshold) that might have been
made on the basis of the NA gene resequencing result alone. The
specimen was collected in 2006 at U S Army Fort Leonard Wood,
MO, and each of these most similar sequence records represented
a NA gene from various circulating type B influenza virus strains
collected during the same influenza season.
The RPM-Flu microarray includes four influenza virus matrix
gene detector tiles, representing matrix gene sequences from
selected reference strains of A/H1N1(human), A/H3N2(human),
A/H5N1(avian) and B(human) types and subtypes. The results in
Table 2 demonstrate specific discrimination and no apparent
crosstalk between the three type A and the one type B matrix gene
detectors. However for each of the human and avian subtypes of
type A influenza viruses, it is generally the case that all three of the
corresponding type A matrix gene detector tiles generate very
similar and overlapping specimen-specific matrix gene sequences.
We have reviewed the lists of most similar sequence records
returned by BLAST analysis of RPM-Flu assay-generated gene
sequences from 12 different human (seasonal) A/H1N1 strains and
31 different human (seasonal) A/H3N2 strains.
Among RPM-Flu assay results from the 12 A/H1N1 samples
there were 478, 800, 201, 348 and 312 most similar sequence
records returned from BLAST analysis of sequences generated
from the HA1(H1N1), NA1(H1N1), M(H1N1), M(H3N2), and
NS(H5N1) detector tiles, respectively. Without exception, each of
these most similar sequence records represents an A/H1N1 strain,
including the 660 sequence records found to match the RPM-Flu
sequences generated from the RPM-Flu M(H3N2) and NS(H5N1)
detector tiles. Among the 31 A/H3N2 samples there were 754,
189, 1267, and 1678 most similar sequence records returned from
the HA3(H3N2), NA2(H3N3), M(H1N1), and M(H3N2) detector
tiles, respectively, and every one of these sequence records
represents an A/H3N2 strain.
However, the NS (H5N1) detector tile generated 109 specimen-
specific NS gene sequences from several of the A/H3N2 samples,
and only 19 of the most NS gene sequence records were from A/
H3N2 strains. The other NS gene sequence records that were
found by BLAST to be most similar to the sequences generated
from assays of A/H3N2 specimens represent subtypes A/H2N2
(12), A/H1N1 (73), A/H11N9 (2), A/H6N2 (2) and A/H3N6 (1).
These results suggest that circulating strains of subtype A/H3N2
harbor diverse NS gene sequences, variations that presumably
arise from frequent co-infections and genome segment reassort-
ments in the field. On the other hand, the subtype A/H1N1
specimens led to RPM-Flu assay-generated NS gene sequences
Table 1. Influenza type A and type B detector tile sequences and RPM-Flu assay-based identification of gene sequences by RPM-
Flu assay of FluMist trivalent vaccine.
RPM-Flu detector title prototype sequences C3 Score E-value SNPs
a
Best matching sequence record (BLAST/
GenBank)
Hemagglutinin genes
A/New Caldedonia/20/1999 (H1N1) 64.0 1e-180 0/1039 A/New Caledonia/20/1999 (H1N1)
A/Canterbury/125/2005 (H3N2) 75.0 1e-180 6/1176 A/Wyoming/3/2003 (H3N2)
B/Malaysia/2506/2004 40.6 1e-155 10/451 B/Jilin/20/2003
B/Shanghai/361/2002 82.2 1e-180 6/750 B/Jilin/20/2003
Neuraminidase genes
A/New Caldedonia/20/1999 (H1N1) 78.2 1e-180 0/971 A/New Caledonia/20/1999 (H1N1)
A/Canterbury/125/2005 (H3N2) 80.7 1e-180 7/999 A/Wyoming/3/2003 (H3N2)
B/Malaysia/2506/2004 61.7 1e-180 3/826 B/Jilin/20/2003
b
Matrix genes
A/Canterbury/100/2000 (H1N1) 69.5 1e-180 6/630 A/Ann Arbor/6/1960 (H2N2)
A/Canterbury/125/2005 (H3N2) 69.5 1e-180 14/626 A/Ann Arbor/6/1960 (H2N2)
B/Memphis/13/2003 81.6 1e-180 11/796 B/Ann Arbor/1/1966
aNumber of observed single base polymorphisms (SNPs), as single base mismatches of detector and specimen gene sequences that are flanked by consensus base calls/
number of specific base calls. The A/H1N1 detector tile and vaccine specimen hemagglutinin and neuraminidase gene sequences are concordant (bold font,
underlined).
bThe original RPM-Flu analysis on 21 Aug 2007 returned four best matching neuraminidase gene sequence records, as B/Yamagata/1246/2003, B/Taiwan/102/2005, B/
Bangkok/460/2003, and B/Roma/4/2002. When subjected to BLAST analysis again on 09 Nov 2008, two more best matching neuraminidase gene sequence records
were returned, as B/Taiwan/34/2004 and B/Jilin/20/2003. The actual influenza type B vaccine strain was B/Jilin/20/2003, but its neuraminidase gene sequence was not
entered into the GenBank database until 21 Jul 2008.
doi:10.1371/journal.pone.0008995.t001
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subtype A/H1N1 strains.
Although it appears that the RPM-Flu assay-generated M gene
sequences may have some utility to differentiate human A/H1N1
and human A/H3N2 subtypes, the NS gene sequences do not
appear to be so reliable for the purpose of inferring A/HN
subtype. This consideration will appear again later in RESULTS
with the subject of indirect, inferred A/HN subtyping of type A
avian influenza viruses.
Clinical Sensitivity and Clinical Specificity of the RPM-Flu
Assay for Human Type A Influenza Viruses
The RPM-Flu assay was implemented in a blinded analysis of
several hundred clinical specimens from the respiratory infectious
disease archives at NHRC. Selected throat swab specimens had
been collected over the period 2005–2007 from basic military
trainees at several installations in the United States. The subjects
were evaluated at the time of specimen collection and associated
with one of three cohorts: apparently healthy and afebrile
Table 2. Detection of specific HA, NA and M gene sequences from individual type A influenza virus reference strains or trivalent
vaccine mixture of reference strains.
Template R
NHRC
A/H1N1
NHRC
A/H3N2
NHRC
type B
Fluvirin
vaccine
USDA
A/H4N6
USDA
A/H7N1
USDA
A/H8N4
NAMRU
A/H10N7
USDA
A/H14N5
HA Gene Detectors
HA1(H1N1) human 76.5 (4.3) (1.9) 91.4 (1.2) (1.9) (0.8) (1.4) (1.0)
HA2(H3N2) human (4.0) (4.6) (2.1) (1.8) (1.3) (2.3) (1.2) (0.4) (2.1)
FLUAHA3 human (2.6) 89.4 (3.0) 94.3 (3.9) (6.9) (3.3) (0.0) (4.1)
FLUBHA human (5.9) (9.6) 31.0 95.9 (4.2) (3.1) (3.5) (1.9) (2.4)
FLUAHA3 avian (3.5) (7.0) (2.9) (8.4) (4.9) (4.4) (1.8) (0.0) (3.3)
FLUAHA4 avian (3.3) (6.3) (1.8) (2.0) 65.0 (0.7) (0.6) (1.1) (5.6)
HA5(H5N1) avian (5.1) (7.5) (3.6) (2.5) (2.3) (2.3) (2.4) (0.4) (1.9)
FLUAHA6 avian (3.3) (5.1) (1.6) (2.3) (1.3) (1.5) (2.2) (1.4) (1.6)
FLUAHA7 avian (2.4) (6.6) (3.7) (5.6) (2.3) 88.5 (3.0) (2.9) (4.3)
FLUAHA8 avian (3.3) (2.8) (1.6) (3.0) (0.9) (1.6) 76.4 (0.0) (1.4)
FLUAHA9 avian (2.5) (5.8) (3.9) (3.4) (2.5) (1.5) (2.7) (1.5) (2.9)
HA1(H1N1)0 avian (2.9) (5.7) (3.0) (0.3) (1.2) (4.9) (0.3) 61.8 (0.7)
HA1(H1N1)1 avian (4.5) (5.1) (4.0) (1.7) (4.0) (3.4) (3.4) (2.3) (2.5)
HA1(H1N1)2 avian (2.1) (4.5) (0.6) (0.7) (0.3) (0.5) (2.4) (0.3) (0.0)
HA1(H1N1)3 avian (2.1) (6.1) (1.6) (1.5) (0.4) (0.3) (0.5) (0.0) (0.3)
HA1(H1N1)4 avian (4.2) (8.6) (3.3) (3.3) (5.7) (4.9) (3.4) (2.4) 86.3
HA1(H1N1)5 avian (5.3) (5.8) (3.4) (1.8) (1.2) (4.0) (1.7) (0.0) (1.8)
HA1(H1N1)6 avian (3.9) (4.8) (2.6) (1.2) (0.4) (0.4) (0.8) (0.4) (0.3)
NA Gene Detectors
NA1(H1N1) human 84.9 (6.9) (2.5) 87.8 (2.7) 14.0 (2.1) (1.4) (3.0)
NA2(H3N2) human (4.7) 84.9 (1.5) 96.8 (2.1) (3.2) (0.9) (0.7) (0.7)
FLUBNA human (2.8) (4.8) 13.7 98.0 (0.8) (2.0) (1.7) (0.9) (2.7)
NA1(H1N1) avian (8.0) (8.3) (1.8) (6.1) (2.5) 57.5 (3.9) (1.0) (5.9)
FLUANA3 avian (3.8) (5.3) (3.1) (0.8) (1.3) (1.9) (1.1) (0.3) (2.9)
FLUANA4 avian (3.2) (4.4) (2.5) (2.5) (3.1) (9.8) 67.7 (0.0) (5.5)
FLUANA5 avian (5.4) (9.8) (4.4) (2.9) (4.4) (5.2) (4.7) (1.5) 66.3
FLUANA6 avian (6.4) (7.9) (3.9) (5.3) 85.5 (8.6) (5.4) (1.8) (7.4)
FLUANA7 avian (5.5) (7.7) (4.4) (3.3) (3.7) (4.9) (3.0) 23.1 (3.0)
FLUANA8 avian (5.9) (7.6) (4.4) (6.1) (6.6) (5.0) (5.6) (1.1) (5.2)
FLUANA9 avian (4.7) (6.9) (1.6) (1.5) (3.8) (3.7) (2.9) (0.0) (1.7)
M Gene Detectors
M(H1N1) 88.7 51.0 (2.8) 61.6 50.1 50.8 40.4 44.5 66.3
M(H3N2) 60.6 96.5 (2.1) 59.2 45.0 46.2 48.1 42.4 48.6
M(H5N1) 38.1 39.1 (4.8) 37.0 51.2 69.6 45.6 44.1 39.2
FLUBM (4.3) (5.2) 34.3 97.7 (2.6) (2.7) (2.9) (2.3) (2.7)
C3 Scores from RPM-Flu gene sequence detector tiles demonstrate specific and differential detection of human and avian influenza virus A/HN subtypes and human
type B influenza virus in assays with single control templates, field or clinical specimens, or the three-part inactivated virus vaccine mix (A/H1N1, A/H3N2, and B). C3
Scores in smaller font, within parentheses, represent sub-threshold negative detector tile reports.
doi:10.1371/journal.pone.0008995.t002
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and those diagnosed with pneumonia (confirmed by chest x-ray).
A group of 298 specimens were analyzed using both the RPM-
Flu assay and a validated benchmark RT-PCR assay for type A
influenza virus described by Freed et al. [10]. Thirty specimens
were identified as positive for type A influenza virus by both
assays, and only 1 specimen was found to be negative by RPM-Flu
and positive by RT-PCR. The remaining 267 specimens were
found to be negative for influenza virus by both assays. All of the
influenza-positive specimens were from participants that had been
assigned to the FRI cohort.
Table 3 shows the calculation of high clinical sensitivity (97%)
and even higher clinical specificity (100%) of RPM-Flu for detection
and identification of type A human influenza virus, compared with
results from testing the same specimens with the benchmark RT-
PCR-based assay. Similarly high clinical sensitivity and high clinical
specificity of RPM-Flu have been demonstrated with in the same
ensemble of clinical specimens with respect to other simultaneously
targeted pathogens of the assay, when similarly robust RT-PCR test
panels were used for benchmark testing of matched specimens (e.g.
human adenoviruses of subgroups B1, B2 and E; Mycoplasma
pneumoniae; results not shown).
The benchmark RT-PCR type A influenza virus test used to
assess clinical sensitivity and specificity of the RPM-Flu assay does
not distinguish between the A/H1N1 and A/H3N2 subtypes.
However the RPM-Flu assay is capable of simultaneous and
mutually exclusive identification of a detected type A influenza
virus as either seasonal subtype A/H1N1 or seasonal subtype A/
H3N2. Results presented in Table 4 demonstrate this capability
for the 30 specimens representing subtype A/H1N1 (5 specimens)
or subtype A/H3N2 (25 specimens). Differentiation of the two
prevalent subtypes is primarily based upon identification of assay-
generated HA and NA sequences as matching HA1 or HA3 and/
or NA1 or NA2, respectively. A secondary inference of A/HN
subtype may be based on which of the M gene detectors M(H1N1)
or M(H3N2) has the higher C3 Score. These indications of type A
human influenza subtype are completely concordant with the
corresponding subtypes associated with the most similar M gene
sequence records from BLAST analysis of the sequences generated
from both the M(H1N1) and the M(H3N2) detector tiles.
In the course of increasing prevalence of oseltamivir-resistant
strains of A/H1N1 and amantadine-resistant strains of A/H3N2,
the NHRC has implemented a new RT-PCR panel to determine
the A/H1 or A/H3 subtype for specimens already shown to be
type A influenza virus-positive by the earlier RT-PCR panel
(David Metzgar, Chris Myers, personal communication). They
have also validated the assay by demonstrating concordance of
subtyping results from new RT-PCR panel with a cell culture/
hemagglutinin immunofluorescence assay (HAI). Type B influenza
virus-positive specimens (identified from the first tier RT-PCR
typing panel) were negative controls for the second tier RT-PCR-
based Type A subtyping panel.
Twelve isolates from the 2008–2009 influenza season, six each
testing positive for A/H1 or A/H3 by the RT-PCR panel (and
also by culture-HAI), were selected for RPM-Flu analysis. All of
the specimens tested definitively positive in the initial (and only
necessary) RPM-Flu assay as either A/H1N1 or A/H3N2,
matching the results of both the RT-PCR and HAI benchmark
Table 3. Clinical sensitivity and clinical specificity of RPM-Flu
for detection and identification of type A human influenza
virus.
RT-PCR Positive RT-PCR Negative
RPM-Flu Positive 30 0
RPM-Flu Negative 1 267
Clinical Sensitivity=96.8%62.0% (95% confidence interval)
Clinical Specificity=100.0%60.4% (95% confidence interval)
RPM-Flu assay results for 298 clinical isolates are compared with results from
benchmark RT-PCR test for type A influenza virus.
doi:10.1371/journal.pone.0008995.t003
Table 4. RPM-Flu assay results C3 scores of six detector tiles
for detection and identification of A/H1N1 and A/H3N2
influenza virus subtypes.
Detector tile R HA1 HA3 NA1 NA2 M (H1N1) M (H3N2)
A/H1N1-positive
specimens
NHRC_117 76.5 84.9 88.7 50.6
NHRC_051 35.4 42.1 75.0 31.1
NHRC_022 27.1 38.8 81.2 34.4
NHRC_157 14.4 14.7 15.2
NHRC_010 13.2 14.1
A/H3N2-positive
specimens
NHRC_044 89.4 84.8 51.0 96.5
NHRC_053 89.0 87.5 49.0 93.6
NHRC_396 78.1 79.7 43.5 91.9
NHRC_075 62.9 69.0 39.3 91.6
NHRC_154 73.0 6.8 37.1 90.8
NHRC_388 72.4 64.3 36.4 88.4
NHRC_189 59.0 59.5 35.7 87.1
NHRC_080 56.1 56.1 36.8 86.2
NHRC_385 60.3 61.2 32.1 84.1
NHRC_016 48.7 51.8 33.0 84.1
NHRC_376 59.8 43.7 32.8 81.9
NHRC_176 59.9 58.0 30.4 80.4
NHRC_393 60.3 44.7 22.2 58.6
NHRC_055 39.0 37.5 22.6 62.1
NHRC_156 38.8 24.6 15.3 42.4
NHRC_040 31.8 30.1 30.5
NHRC_382 36.9 17.0 24.5
NHRC_057 23.6 13.6 42.9
NHRC_204 13.5 27.9
NHRC_049 24.6 21.8
NHRC_378 22.3 11.3
NHRC_366 19.0 10.1
NHRC_026 22.7
NHRC_390 18.2
NHRC_380 14.2
Each specimen was independently corroborated as positive for type A influenza
virus by benchmark RT-PCR analysis, noting that that assay does not resolve the
subtype. The A/H1N1- and A/H3N2-positive specimens identified from RPM-Flu
results are listed in descending order relative to the sum of positive detector tile
C3 Scores (for H, N, and M). Empty cells indicate detector tiles that did not meet
the relaxed detection and reporting threshold (C3 Score ,10).
doi:10.1371/journal.pone.0008995.t004
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reinforcing the point of mutually exclusive detection and
identification of specimen-specific gene sequences from the HA1
and NA1 detector tiles (as A/H1N1) or from the HA3 and NA2
detector tiles (as A/H3N2).
The results for M gene sequences from both the M(H1N1) and
the M(H3N2) detector tiles for both sets of specimens shown in
Table 5 again display significant crosstalk as overlapping and highly
similar assay-generated sequences. In every example the two M
gene sequences of an individual specimen, generated from the
M(H1N1) and M(H3N2) gene detector tiles, are consistent with the
A/HN subtype directly indicated the HA and NA gene sequences
generated in the same RPM-Flu assay of the same specimen.
All 30 of the influenza-positive specimens described above were
also reported by the individual RPM-Flu assays to be positive for
at least one and up to six other viral and/or bacterial respiratory
pathogens, including adenovirus, rhinovirus, coronavirus, Morax-
ella catarrhalis, Staphylococcus aureus, Streptococcus agalactiae, Haemophilus
influenzae, Neisseria meningitidis, Pseudomonas spp., Streptococcus mitis,
and Streptococcus pneumoniae. There was no obvious correlation of
the distributions of other co-infecting pathogens with the
particular subtype of infecting influenza virus, or with particular
specimen collection venue(s). There was no data on clinical
presentation or outcomes to correlate with particular states of co-
infection(s).
We considered whether or not there may be interference with
the detection and identification of specific influenza viruses in
specimens that test positive in RPM-Flu assays for other viral and
bacterial respiratory pathogens. The background distribution of
C3 Scores for detection and identification of influenza viruses was
estimated from RPM-Flu assays of 14 different blank samples
(water or transport media negative controls). The average C3
Score of the 39 type A and type B influenza virus detector tiles to
be 1.761.1 (N=14, results not shown).
Another set of 25 specimens were found to be negative for
influenza virus by both RPM-Flu and benchmark RT-PCR tests,
while the same RPM-Flu assays reported the specimens to be
positive with apparently high load (C3 Score.75) of at least one
other viral or bacterial respiratory pathogen (results not shown).
Simultaneous pathogen targets of the RPM-Flu assay that
apparently do not interfere with detection and identification of
influenza viruses include adenovirus (types Ad4, Ad7), coronavirus
(strains OC43, 229E, NL63), rhinovirus (types A, B), metapneu-
movirus (types A, B), parainfluenzavirus (types 1, 2, 3), respiratory
syncytial virus (RSV types A, B), Chlamydophila pneumoniae,
Haemophilus influenzae, Klebsiella pneumoniae, Moraxella catarrhalis,
Mycoplasma pneumoniae, Neisseria meningitidis, Pseudomonas aeruginosa,
Staphylococcus aureus (including MRSA strains), Streptococcus agalactiae,
Streptococcus pneumoniae, and Streptococcus pyogenes.
Informational Specificity of RPM-Flu: Influenza Virus
Genotypes and Resistance to Antiviral Agents
Subtype A/H3N2 influenza virus and Matrix (M) gene-
based resistance to amantadine-like antiviral agents. The
25 A/H3N2-positive clinical specimens from the ensemble of 298
specimens described in the preceding section were collected
between January 2007 and March 2007, at five different military
basic training venues (Great Lakes Naval Training Station, IL;
Marine Corps Recruit Depot, CA; Army Fort Leonard Wood,
MO; Army Fort Jackson, SC; Army Fort Benning, GA). All but
one of the RPM-Flu assay-generated HA3 gene sequences were
most similar to BLAST-returned sequence records of A/H3N2
isolates that Nelson et al [11] associated with either major ‘‘clade
a’’ from the 2006–2007 influenza outbreaks in the United States,
or from the ‘‘N-lineage clade’’, a lineage originating from the
2005–2006 influenza season and continuing to circulate
nationwide during the 2007–2008 season. The HA3 gene
sequence from a single A/H3N2 specimen was found to be most
similar to sequence records that Nelson et al [11] associated with
the 2006–2007 ‘‘minor clade b’’. This minor clade b to represents
a subpopulation of amantadine-sensitive A/H3N2 strains, in
contrast to the resistant phenotype of the strains with the majority
of circulating N- and a-clade strains.
Table 5. Concordance of RPM-Flu determination of A/H1N1 and A/H3N2 subtypes with benchmark RT-PCR HA1/HA3 subtyping
panel and cell culture-HAI HA1/HA3 subtyping assays.
C3 Scores from RPM-Flu Detector Tiles Diagnostic Assay
Specimen (_ _2008) HA1 NA1 M(H1N1):M(H3N2) HA3 NA2 RPM-Flu RT-PCR Culture-HAI
NHRC_SV_418 72 71 87.48
a 4 6 A/H1N1 A & H1 A & H1
NHRC_SV_413 64 71 81.46
a 3 7 A/H1N1 A & H1 A & H1
NHRC_SV_415 35 42 75.31
a 7 13 A/H1N1 A & H1 A & H1
NHRC_SV_416 8 12 20.10
a 2 6 A/H1N1 A & H1 A & H1
NHRC_SV_411 15 22 35.17
a 4 10 A/H1N1 A & H1 A & H1
NHRC_AML_10622 73 83 84.45
a 0 0 A/H1N1 A & H1 A & H1
NHRC_JB_46159 2 0 15,56
b 43 34 A/H3N2 A & H3 A & H3
NHRC_JB_30553 1 0 18,62
b 45 34 A/H3N2 A & H3 A & H3
NHRC_JB_35105 1 1 3,17
b 19 7 A/H3N2 A & H3 A & H3
NHRC_JB_65320 1 0 3,23
b 18 7 A/H3N2 A & H3 A & H3
NHRC_JB_46162 1 1 21,64
b 52 42 A/H3N2 A & H3 A & H3
NHRC_AML_10601 1 1 43,96
b 80 79 A/H3N2 A & H3 A & H3
aBLAST analysis of RPM-Flu assay-generated sequences from both of these M gene detector tiles returned most similar M gene sequence records that exclusively
represent subtype A/H1N1 strains.
bBLAST analysis of RPM-Flu assay-generated sequences from both of these M gene detector tiles returned most similar M gene sequence records that exclusively
represent subtype A/H3N2 strains.
doi:10.1371/journal.pone.0008995.t005
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region of influenza virus M gene have been reported to confer
some level of in vitro amantadine resistance [12,13]. This suggested
examination of the RPM assay-generated M gene sequences from
these A/H3N2-positive specimens, to evaluate possible correla-
tions with resistance of the subject isolates to amantadine.
Figure 3 shows alignment of M gene sequences from 18 of the
25 A/H3N2-positive specimens, together representing all three of
the clades described by Nelson et al [11].
The M gene sequences detected by RPM-Flu assay of the 24
amantadine-resistant N-lineage or clade-a specimens all reveal -
AAT- as asparagine (N) codon 31 of the M2 peptide, a genotype
consistent with amantadine resistance. The matrix gene sequence
of the outlier clade-b specimen (NHRC_393) reveals -AGT- as
serine (S) codon 31 of the M2 peptide, a genotype consistent with
an amantadine-sensitive phenotype.
Subtype A/H1N1 influenza virus and neuraminidase NA1
gene-based resistance to oseltamivir-like antivirals. The
five A/H1N1-positive clinical specimens from the ensemble of 298
specimens described in the preceding section were collected
between January 2007 and March 2007, at two different military
basic training venues (Army Fort Jackson, SC; Army Fort
Benning, GA). BLAST analysis of the five RPM-Flu-detected
HA1 gene sequences returned most similar reference sequence
records including those that Nelson et al. [11] associated with A/
H1N1 Major Clade A from the 2006–2007 outbreaks of influenza
in the United States. Global surveillance during the two most
recent influenza seasons (2007–2009) has revealed that most
circulating A/H1N1 isolates are now resistant to oseltamivir,
compared with oseltamivir sensitivity of most if not all A/H1N1
isolates from the 2006–2007 influenza season [14,15 (updated 13
June 2008)]. These more recent A/H1N1 strains appear to have a
resistance phenotype due to mutation at the viral NA1 gene
H275Y locus [16].
Neuraminidase gene sequences were detected and compared at
this locus from RPM-Flu assays of specimens from the earlier
2006–2007 season and more recent 2007–2008 season specimens
provided by NHRC for analysis. As shown in the Figure 4, the
RPM-Flu assay-generated NA1 gene sequences from the older
ensemble of clinical specimens (2006–2007) were concordant with
those of the oseltamivir-sensitive, A/New Caldedonia/20/1999
(H1N1) RPM-Flu detector tile strain. BLAST analysis of these
NA1 gene sequences returned most similar records including the
oseltamivir-sensitive A/Ohio/UR06-0591/2007 and A/Oregon/
UR06-0609/2007 strains. The ‘@’ symbol in the inset indicates
the C-T transition mutation corresponding to the H275Y
mutation. On the other hand, the examples shown in the bottom
half of the inset, representing 2007–2008 oseltamivir-resistant
specimens from NHRC, had runs of 10 to 20 uncalled bases (N)
spanning the NA1 gene’s H275Y oseltamivir resistance locus.
These results do not explicitly corroborate the H275Y resistance
genotype, although they are consistent with diminished re-
sequencing efficiency at sites of mismatching detector tile and
specimen gene sequences. These runs of N-calls suggest two or
more proximal nucleotide mismatches may be present at this NA1
gene locus of the selected NHRC 2008 specimens. There were 115
Figure 3. Alignment of M (matrix) gene sequences from 18 of 25 A/H3N2-positive specimens, representing three circulating 2006–
2007 seasonal clades described by Nelson et al [11]. Twenty-four of the samples represent amantadine-resistant N-lineage or clade-a
specimens, and each of these reveals -AAT- as asparagine (N) codon 31 of the M2 peptide (locus outlined in red box), a genotype consistent with the
amantadine resistance phenotype. The matrix gene sequence of the single outlier clade-b sample (NHRC_393) reveals -AGT- as serine (S) codon 31 of
the M2 peptide, a genotype consistent with the amantadine-sensitive phenotype.
doi:10.1371/journal.pone.0008995.g003
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full-length RPM-Flu assay-generated NA1 gene sequences, and
five of these sequence records indicated a second, H275Y-
proximal mutation (at positions of asterisks on either side of the
@ symbol). Any such pair of proximal mismatches in a specimen
gene sequence (template) could disrupt hybridization of the sets of
25-nucleotide oligomer probes used to determine basecalls by the
RPM-Flu re-sequencing method.
Future iterations of the RPM-Flu microarray design could
provide one or more alternative NA1 gene sequence detector
subtiles. Such assay design iterations would enable future RPM-
Flu assays to deliver more explicit first-assay characterization of
the oseltamivir genotype and phenotype.
RPM-Flu Sensitivity: Limits of Detection for A/H1N1 and
A/H3N2 Isolates from the 2008–2009 Influenza Season
An isolate of subtype A/H1N1 and another of subtype
A/H3N2 were selected by NHRC for single-passage propagation
in MDCK cell cultures, followed by infectivity titrations in
replicate shell vial cultures. The resulting neat stocks of
BRD10622N(H1N1) and BRD10601(H3N2) were determined to
contain 3.16610
7 TCID50/ml and 1.78610
7 TCID50/ml,
respectively.
These two titered stocks were used to determine the analytical
sensitivity of the RPM-Flu, by blinded assays of samples extracted
from triplicate three-fold serial dilutions in the range of 1:1,000 to
1:2,187,000. Background C3 Scores were used as thresholds for
reporting detection of either A/H1N1 or A/H3N2 in these limit
dilution assays (as opposed to the relaxed and stringent thresholds
used for reporting results from assays of clinical or field specimens).
The background detector tiles represent 25 non-A/H1N1 and
non-A/H3N2 detector tiles from each individual RPM-Flu assay,
and a positive detection was reported if one of the target-specific
detector tiles from the following lists had C3 score at least 3.29
standard deviations greater than the background mean C3 Score
(p,0.001).
Figure 5 and Figure 6 illustrate the results of these endpoint
dilution titrations of the titered A/H1N1 and titered A/H3N2
stocks, respectively, plotting the average highest C3 Score of A/
H1N1 or A/H3N2 detector tiles for each of the triplicate assays at
each dilution level. The percent positive assays (3/3, 2/3, 1/3
and/or 0/3) are also shown for the A/H1N1triplicate dilutions
(Figure 5) and for the A/H3N2 triplicate dilutions (Figure 6).
These unblinded dilution titration assay results were used to
estimate 95% positive detection endpoints. Then one of the A/
H1N1 and two of the A/H3N2 dilution tiers were expanded from
three to twenty replicates, in order to demonstrate the high
likelihood ($95%) of positive detection and identification at the
indicated dilution of the respective neat stocks.
From these results RPM-Flu assay, the 95% positive endpoint
dilution limits of detection (LoD) be 3 TCID50 for the A/H1N1
titered stock preparation and 6 TCID50 for the A/ H3N2 titered
stock preparation.
From the total of 41 independently extracted dilution specimens
of the subtype-confirmed and titered A/H1N1 stock (Figure 5), 37
were reported to be influenza-positive by RPM-Flu assay, and all
of these assays correctly reported by the RPM-Flu assays as
subtype A/H1N1 (100% specificity). From a total of 58
independently extracted dilution specimens of the subtype-
confirmed and titered A/H3N2 stock (Figure 6), 44 were reported
to be influenza-positive by RPM-Flu assay, and all of these assays
correctly reported by the RPM-Flu assays as subtype A/H3N2
(100% specificity). A total of 268 specimens from the NHRC
clinical specimen ensemble were found to be negative for type A
influenza virus by the RPM-Flu assay and 267 of these were also
reported to be influenza virus-negative by benchmark RT-PCR
assays for type A influenza virus, supporting the conclusion of
100% subtyping specificity for the RPM-Flu test.
Figure 4. Comparison of RPM-Flu assay-generated NA1 (neuraminidase) gene sequences from two ensembles of clinical specimens,
collected in 2006–2007 and in 2008, respectively. The older specimens have NA1 gene sequences that are concordant with those of the
oseltamivir-sensitive, A/New Caldedonia/20/1999 (H1N1) RPM-Flu detector tile strain, including the determinant –CAT– histidine (H) codon at peptide
position 275 (aligned locus in red box). BLAST analysis of these NA1 gene sequences returned most similar records including the oseltamivir-sensitive
A/Ohio/UR06-0591/2007 and A/Oregon/UR06-0609/2007 strains. The ‘@’ symbol in the inset indicates the C-T transition mutations encoding tyrosine
(Y) at this locus of more recent strains such as A/South Carolina/06/2008 and A/Texas/16/2008. Three specimens (NHRC_413, _415, and _418) were
also collected in 2008, and these failed to generate sequence through this locus from the oseltamivir-sensitive detector tile genotype. These results
do not explicitly corroborate the H275Y resistance genotype, although they are consistent with diminished re-sequencing efficiency at sites of
mismatching detector tile and specimen gene sequences. These runs of N-calls suggest two or more proximal nucleotide mismatches may be present
at this NA1 gene locus of the selected NHRC 2008 specimens.
doi:10.1371/journal.pone.0008995.g004
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A Avian Influenza Virus Subtypes Based upon RPM-Flu
Assay-Generated HA and NA Gene Sequences
A collection of 23 reference strain specimens, representing
diverse type A avian influenza virus subtypes, were propagated in
embryonated eggs by SEPRL, then extracted for purification of
total nucleic acid as input to RPM-Flu assays.
Table 6 presents the results for 19 of these 23 specimens
reported by the RPM-Flu assays to be positive for avian influenza
virus. In each case the RPM-Flu assay-generated HA and NA gene
sequences identified the particular A/HN subtype that precisely
matched the unblinded identifications of each reference strain.
BLAST/GenBank analysis of these RPM-detected query sequenc-
es returned best matching sequence records with the same A/HN
types as determined from the HA and NA detector tile C3 Scores.
For 14 of these specimens, the single or multiple most similar HA
and NA gene sequence records included the particular reference
strain actually provided by SEPRL for analysis. These instances
are highlighted as entries with flanking asterisks in the right
column of Table 6).
The RPM-Flu assay of specimen USDA_13 was reported
negative for detection of avian influenza virus, but the same assay
also reported the specimen to be positive for avian metapneumo-
virus. This was revealed to be a correct result after unblinding of
the specimen identification as a non-influenza control Type C
avian metapneumovirus.
Three avian influenza virus-negative RPM-Flu assay results
were also concordant with subsequently unblinded specimen
information. USDA_5 was RPM-Flu negative for avian influenza
and later confirmed to have been from an unsuccessful inoculation
of the egg culture.
USDA_8 was reported by RPM-Flu assay to be A/H11N9, and
while the initial identification from SEPRL was subtype A/H9N2,
the original specimen apparently represented a mixed infection of
H11N9 and H9N2. The HA component of the specimen was
subjected to de novo gene sequencing and determined to be A/H11
strain. The RPM-detected neuraminidase sequence (868 bp,
C3=88.7) unequivocally matched A/N9; the mean C3 Score of
all other neuraminidase detector tiles in the assay was 3.161.6
(N=10).
USDA_16 was correctly negative by RPM-Flu assay for avian
influenza, but unblinding revealed this specimen to be a second
negative control, containing instead avian paramyxovirus type I
(Newcastle disease virus). After receiving this information, another
aliquot of the same nucleic acid preparation from specimen
USDA_16 was tested using an alternative RPM-TEI assay [17] for
detecting tropical and emerging infections. This assay resulted in
successful detection and identification of avian paramyxovirus
type 1.
Specimen USDA_23 was received later as a substitute for the
failed inoculum specimen USDA_5. The RPM-Flu assay of this
specimen resulted in detection of sequence for neuraminidase type
N4, with most similar sequence record representing an A/H8N4
strain. However, no hemagglutinin gene sequences were detected
that met even the relaxed detection threshold. The highest C3
Scores among all RPM-Flu hemagglutinin detector tiles were
Figure 5. Limit of Detection (LoD) determination for seasonal
A/H1N1 strain BRD10622. Neat stock of cell culture lysate (3.166
10ˆ7 TCID50/ml) was diluted 1:1,000 in cell culture media. Triplicates at
this dilution, and at serial three-fold dilutions to 1:2,187,000 were
individually extracted and subjected to RPM-Flu assay. Black circles
indicate average of the maximum C3 Score (from either HA1, NA1 or
M(H1N1) detector tiles) at each dilution, plotted against log10 TCID50
input per assay. Open circles represent the quantal percentage of
positive assays (out of three) at each dilution tier. The open and black
hexagons correspond to a dilution tier at which 20-fold replicates were
assayed to demonstrate the 95% endpoint LoD, in this case
corresponding to single assay input of about 3 TCID50.
doi:10.1371/journal.pone.0008995.g005
Figure 6. Limit of Detection (LoD) determination for seasonal
A/H3N2 strain BRD10601. Neat stock of cell culture lysate (1.786
10ˆ7 TCID50/ml) was diluted 1:1,000 in cell culture media. Triplicates at
this dilution, and at serial three-fold dilutions to 1:2,187,000 were
individually extracted and subjected to RPM-Flu assay. Black circles
indicate average of the maximum C3 Score (from either HA3, NA2 or
M(H3N2) detector tiles) at each dilution, plotted against log10 TCID50
input per assay. Open circles represent the quantal percentage of
positive assays (out of three) at each dilution tier. The open and black
hexagons correspond to a dilution tier at which 20-fold replicates were
assayed to demonstrate the 95% endpoint LoD, in this case
corresponding to assay input of about 6 TCID50.
doi:10.1371/journal.pone.0008995.g006
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neither of these sub-threshold results triggered a positive detection
report.
Lin et al (2009) recently reported another study of avian
influenza viruses using RPM-Flu assays for 24 AH5N1-positive
field and clinical specimens collected by the NAMRU-3 group
from infected birds and humans [18]. Supplemental Table S5
summarizes results from our re-analysis of their original RPM-Flu
assay data (GSEQ FASTA files), presenting C3 Scores as
described in this report for assay-generated sequences from the
subtype-specific HA and NA detector tiles, or from the RPM-Flu
M, NS and PB2 detector tiles (that represent conserved gene
sequences of a prototype A/H5N1 strain).
The RPM-Flu assay-generated HA5 gene sequences of all the
A/H5N1-positive specimens from NAMRU-3 and also of the A/
H5N2 reference strain specimen from SEPRL (Table 6,
USDA_17) were consistent with an extended arginine-rich and
lysine-rich motif spanning the HA5 peptide cleavage site,
consistent with a viral high pathogenicity (HP) phenotype
[19,20]. BLAST analysis of the RPM-Flu detected HA5 gene
sequences from these strains returned most similar sequence
records encoding a similar HP-like HA5 cleavage site motif.
The hemagglutinin RPM-Flu assay-generated HA5 gene
sequence for the A/H5N3 reference strain (Table 6, USDA_14)
had a significant gap of uncalled bases at the HA cleavage site
locus, compared to the HP-like HA gene detector tile sequence A/
Table 6. RPM-Flu Assay detection and subtype identification of avian influenza in reference strain specimens provided by SEPRL.
Blinded sample ID
Highest HA C3
Score
Highest NA C3
Score
RPM-Flu Detection &
Identification Unblinded SEPRL Reference Strain
USDA_ _1 36.6 14.7 A/H1N1 * A/Turkey/Kansas/4880/80 (H1N1) *
USDA_ _2 30.0 85.3 A/H2N8 * A/Herring Gull/DE/677/88 (H2N8) *
USDA_ _3 65.6 78.0 A/H3N2 A/turkey/MN/366767/2005 (H3N2)
USDA_ _4 65.0 85.5 A/H4N6 * A/Blue Winged Teal/OH/240B/88 (H4N6) *
USDA_ _5 6.7 4.6 Negative for avian
influenza virus
No avian influenza virus, Attributed to inoculum failure
USDA_ _6 12.1 18.6 A/H7N2 * A/quail/PA/20304/98 (H7N2) *
USDA_ _7 76.4 67.7 A/H8N4 A/turkey/CO/169118-13/02 (H8N4)
USDA_ _8 11.2 88.7 A/H11N9 Original inoculum as A/chicken/NJ/12220/97(H9N2)
was found to be coinfected with A/H11N9 strain
A/H11 sequence confirmed by DNA sequencing
NA sequence pending
USDA_ _9 39.3 8.8 A/H10N7 A/quail/NJ/25254-22/95 (H10N7)
USDA_ _10 12.0 69.8 A/H11N3 A/chicken/NJ/4645/96(H11N3)
USDA_ _11 74.0 9.5 A/H12N5 * A/duck/LA/188D/87 (H12N5) *
USDA_ _12 16.8 18.0 A/H13N6 * A/Gull/Maryland/1824/1978(H13N6) *
USDA_ _13 9.8 4.9 Negative for avian
influenza virus
No avian influenza virus
Avian metapneumovirus (Colorado strain)
Positive for avian
metapneumovirus
USDA_ _14 64.4 22.8 A/H5N3 * A/duck/Singapore/F119/97 (H5N3) *
USDA_ _15 10.8 30.3 A/H7N3 * A/chicken/Chile(F0)/176822/02 (H7N3) *
USDA_ _16 9.8 6.4 Negative for avian
influenza virus
No avian influenza virus
Avian paramyxovirus type 1
Newcastle Disease Virus California/02
Positive for NDV
using RPM-TEI
USDA_ _17 10.5 19.2 A/H5N2 * A/chicken/Mex/26654-1374/94 (H5N2) *
USDA_ _18 88.5 57.5 A/H7N1 * A/turkey/Italy/4580/99 (H7N1) *
USDA_ _19 66.3 26.1 A/H7N3 * A/chicken/Pakistan/1369-CR2/95 (H7N3) *
USDA_ _20 27.6 24.1 A/H7N7 * A/chicken/Victoria/85 (H7N7) *
USDA_ _21 86.3 66.2 A/H14N5 * A/mallard/Gurjev/263/82 (H14N5) *
USDA_ _22 80.9 17.9 A/H15N9 * A/Shearwater/W. Australia/2576/79 (H15N9) *
USDA_ _23 10.4 57.0 A/H?/N4 No detection of HA sequence.
Best matching record for
NA4 sequence is A/H8N4.
For 14 of these specimens, the single or multiple most similar HA and NA gene sequence records matching sequences from the RPM-Flu assay included the particular
reference strain actually provided by SEPRL for analysis. These instances are with asterisks flanking entries in the right column of Table 6). Other instances, without
asterisks, represent assayed reference strains for which one or both HA and NA gene sequences had not yet been deposited in GenBank, but which were nevertheless
concordant with sequences generated by the RPM-Flu assay.
doi:10.1371/journal.pone.0008995.t006
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and neuraminidase gene sequence records returned by BLAST for
HA and NA gene sequences of USDA_14 included strain A/
duck/Singapore/3/1997 (H5N3), the actual reference strain
submitted (blinded) for RPM-Flu analysis. The encoded hemag-
glutinin gene cleavage site for this reference A/H5N3 strain is
consistent with a low pathogenicity (LP) phenotype.
A/duck/Singapore/3/1997(H5N3) -PQRE----TR/GLF- (LP)
A/Viet Nam/1203/2004 (H5N1) -PQRERRRKKR/GLF- (HP)
These results demonstrate efficacy of RPM-Flu for unequivocal
diagnostic detection and identification of human and avian
influenza virus subtypes, based upon direct determination of
specimen-specific sequences of the hemagglutinin and neuramin-
idase genes. The two negative control specimens, USDA_13 and
USDA_16, demonstrated the capability of the RPM-Flu assay to
identify alternative pathogens to avian influenza virus as
components of a more complete differential diagnosis assay for
cases of avian influenza-like illness.
Prediction of Influenza Virus A/HN Subtype by Inference
from Database Sequence Records That Are Most Similar
to RPM-Flu Assay-Generated M, NS or PB Gene
Sequences
The results presented in Table 6 demonstrated 19 of 19
reference strains of type A avian influenza viruses detected and
correctly identified by corresponding A/HN subtype, based
upon the specific HA and NA gene sequences revealed in the
assays of each specimen. The same assays also generated
specimen-specific M, NS and/or PB2 gene sequences. We used
these results to poll the A/HN subtype(s) of the influenza virus
strains corresponding to BLAST-returned sequence records
found to be most similar to these relatively conserved non-HA
and non-NA gene sequences (Supporting Information - Table
S6, Table S7, Table S8).
BLAST analysis of the M gene sequences from the 19 avian
influenza specimens returned 79 most similar sequence records, of
which 40 (51%) were associated with different A/HN subgroups
than determined from the corresponding specimens’ HA and NA
gene sequences. For five of the 19 specimens there were no most
similar M gene sequences returned to match the specimen’s actual
A/HN subtype (Table S6).
BLAST analysis of the NS gene sequences from the 19 avian
influenza specimens returned 63 most similar sequence records, of
which 41 (65%) were associated with different A/HN subgroups
than determined from the corresponding specimens’ HA and NA
gene sequences. For five of the 19 specimens there were no most
similar NS gene sequences returned to match the specimen’s
actual A/HN subtype (Table S7).
BLAST analysis of the PB2 gene sequences from the 19 avian
influenza specimens returned 58 most similar sequence records, of
which 22 (38%) were associated with different A/HN subgroups
than determined from the corresponding specimens’ HA and NA
gene sequences. Nine of the 19 specimens had no most similar PB2
gene sequences from the same A/HN subtype (Table S8).
These results suggest little predicate value of most type A
influenza virus M, NS or PB2 sequences for determination of the
A/HN subtype of the strain from which these sequences were
identified.
We referred earlier to the complementary set of field and
clinical samples (isolates, not original specimens) of type A avian
influenza viruses provided by NAMRU-3 (Cairo, Egypt) and
analyzed at NRL using RPM-Flu [18]. As noted earlier, Table S5
in SUPPLEMENTAL INFORMATION presents the C3 Scores
from RPM-Flu assay-generated gene sequences data for these
specimens.
Eight samples from this previously referenced set of clinical and
field specimen isolates of avian influenza virus represented
subtypes A/H10N7 (4), A/H7N7 (2), A/H11 (1) or A/H13 (1).
In marked contrast to results from RPM-Flu assay-generated HA
and NA gene sequences, there was poor correspondence of the
actual specimen A/HN subtypes with the subtypes of sequence
records returned from BLAST analysis of the assay-generated M,
and NS gene sequences. Of 30 most similar M gene sequence
records only 5 were from A/HN subtypes matching the subtypes
of the corresponding specimens (Table S6). None of the 11 most
similar NS gene sequence records matched the A/HN subtypes of
the corresponding specimens (Table S7). There were no PB2 gene
sequences reported from assays of these eight (non-A/H5N1)
specimens (Table S5).
Twenty-one of the remaining specimens of the set reported by
Lin et al [18] were of subtype A/H5N1, and the RPM-Flu assay
results for these specimens are also included in Table S1, as C3
Scores for the sequences generated from the corresponding HA5,
NA1, M, NS and PB2 gene detector tiles. For these 21 A/H5N1-
positive specimens, the BLAST analyses of assay-generated M, NS
and PB2 gene sequences exclusively represented subtype A/H5N1
avian influenza viruses, as 255 M gene, 146 NS gene and 310 PB2
gene sequence records.
This result for A/H5N1strains is reminiscent of the results
presented earlier for subtypes A/H1N1 and A/H3N2 and type B
human influenza virus sequence records that are found to be most
similar to RPM-Flu assay-generated M, NS and PB2 gene
sequences from the corresponding types and subtypes. It is
interesting to consider that these results may reflect the highly
biased over-representation of samples A/H5N1 sequences in the
genome sequence database(s), reflecting much more of the natural
diversity of non-HA and non-NA gene sequences than in more
sparsely sampled (but naturally far more prevalent) avian influenza
virus subtypes.
Discussion
Rapid and cost-effective microarray-based resequencing
(RPM) of influenza virus hemagglutinin and neuraminidase
genes provides sensitive detection and specific identification for
types and subtypes of previously known as well as emergent
strains and variants. These capabilities of the RPM platform
stand out very favorably on comparisons with the most recently
adopted diagnostic methodologies that are based on real-time
reverse-transcription, polymerase chain reaction methods (RT-
PCR). The FDA-cleared CDC rRT-PCR Flu Panel (510(k)
080570) enables detection and discrimination of influenza viruses
having HA subtype components A/H1, A/H3 and A/H5, and
also type B influenza virus. However the test provides no
a s s u r a n c et h a tap o s i t i v et e s tr e s u l t correctly identifies one of the
inferred target subtypes A/H1N1, A/H3N2 or A/H5N1; there is
no neuraminidase subtype component evaluated as part of the
test. Results presented in this report demonstrate that the
TessArray RPM-Flu detect and identifies these three targeted
subtypes of interest, but also directly distinguishes each of them
among the 9 different A/HN subtype categories, or from the
background of 144 combinatorial variations of influenza virus A/
HN subtypes.
Sensitivity
The RPM-Flu assay leverages a multiplexed RT-PCR-like
strategy to rapidly (,1 hour) amplify trace quantities of specific
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present in a specimen. Results from this report demonstrated that
the 95% endpoint limits of detection (LoD) for seasonal A/
California-NHRC/BRD10622N/2009(H1N1) and seasonal A/
California-NHRC/BRD10601N/2009(H3N2) influenza virus
strains were 2.8 infectious doses (TCID50) and 5.8 TCID50,
respectively. These strains have not been serially passaged at high
multiplicity in either egg or MDCK cell cultures, so it is not likely
that accumulations of defective viral particles would favorably bias
determination of sensitivity with genome-based assays relative to
infectious doses. Furthermore, these two strains were not selected a
priori for favorable match of viral sequences with oligonucleotide
primers used for target gene sequence amplification. The observed
RPM-Flu LoD for each strain is of similar order of magnitude as
comparable estimates of analytical sensitivity reported from RT-
PCR based methods, Table 7.
Specificity
Each RPM assay of a single specimen is capable of generation
from hundreds to thousands of nucleotides of multiple targeted
pathogen gene sequence(s). Gene sequences generated directly
from RPM-Flu assays may specify determinants of particular
target pathogen phenotypes (virulence, drug resistance, host
range, etc.), or support forensic queries of identity of detected
strains in different specimens, or support genome diversity-based
epidemiological tracking in the course of an infectious disease
outbreak.
RPM-Flu assay-generated nucleotide sequences representing one
or more target genes of each detected pathogen convey significantly
more informative specificity than can be obtained from any singlet
or multiples of RT-PCR tests. Some RT-PCR protocols are
designed to glean additional detail regarding detected pathogen
genotypes, through results from multiple (serially executed) RT-
PCR panels, but this approach imposes additional testing costs and
time delays and yield far less specific information than actual target
gene sequences provided from a single RPM assay.
Some platforms claim to differentiate selected type A influenza
virus subtypes based upon indirect detection or specification of
non-HA and non-NA viral gene sequences [21,22]. Results in this
report of RPM-Flu assay-generated viral gene sequences from a
variety of reference strains indicate that matrix M gene sequences
are correlated with the subtypes of only seasonal human A/H1N1
and seasonal A/H3N2 strains. In general, however, non-HA and
non-NA viral gene sequences do not support reliable inference of
type A influenza virus subtype.
Multiplicity
The RPM-Flu assay panel simultaneously addresses 30 different
categories of viruses and bacteria that are more or less likely to be
encountered in specimens related to respiratory infections
(Figure 1, Figure S1). Each assay simultaneously enables detection
and identification of targeted pathogens from one or more of 188
different target gene resequencing detector tiles.
For comparison, the recently FDA-cleared LuminexH Respira-
tory Viral Panel (RVP) Multiplex Nucleic Acid Detection Assay
Respiratory Virus Panel (510(k) K063765) is a twelve-plex RT-
PCR panel for detection and differentiation of a few strains and
types of respiratory viruses including adenovirus, influenza A virus
(as A/H1 or A/H3), respiratory syncytial virus, parainfluenza
virus, metapneumovirus and rhinovirus (no bacterial respiratory
pathogens tested). The RVP assay yields no specimen-specific viral
gene sequences that could be used for more detailed identification
and differentiation of detected virus strains and variants of
detected virus(es).
For human and avian type A influenza viruses in particular, the
RPM-Flu provides direct detection and identification capability for
any of the combinatorial 144 A/HN subtypes that may be present
in a specimen, using an ensemble of 39 different influenza virus
target gene resequencing detectors. The Luminex RVP multiplex
RT-PCR panel uses three of its twelve primer-probe sets to detect
type A influenza virus (M gene-specific primer pair) and
distinguish A/H1 from A/H3 (HA1- and HA3-specific primer
Table 7. Similar analytical sensitivity for seasonal influenza virus detection using RPM-Flu and rRT-PCR panel assays.
Platform Tested Strains Limit of Detection (LoD)
Resequencing Microarray:
RPM-Flu A/California-NHRC/BRD10622N/2009(H1N1) 3 TCID50
RPM-Flu A/California-NHRC/BRD10601N/2009(H3N2) 6 TCID50
rRT-PCR Panel:
JBAIDS
a A/Hawaii/15/2001 (H1N1) 2 TCID50
JBAIDS
a A/Texas/71/2007 (H3N2) 15 TCID50
CDC
a A/New Caledonia/20/1999(H1N1) 16 EID50,1T C I D 50
CDC
a A/Hawaii/15/2001(H1N1) 32 EID50,2T C I D 50
CDC
a A/New York/55/2004(H3N2) 160 EID50,10 TCID50
CDC
a A/Wisconsin/55/2004(H3N2) 32 EID50,2T C I D 50
The Limit of Detection (LoD) for seasonal A/H1N1 and seasonal A/H3N2 influenza viruses are presented as the number of tissue culture (TCID50) or egg culture (EID50)
infectious units used for each assay that are demonstrated to result in .95% positive assay outcomes. The relation of tissue culture and egg culture infectious units
typically vary with respect to specific influenza virus strain and inoculum. For this table an estimated ratio of 16 EID50 : 1 TCID50 is based upon results of testing the same
A/Hawaii/15/2001 (H1N1) strain by both the JBAIDS and CDC rRT-PCR panels.
aThe recently FDA-cleared 510(k)080570 the ‘‘CDC Human Influenza Virus Real-time RT-PCR Detection and Characterization Panel’’ is a test designed to specifically
detect contemporary A/H1, A/H3 and A/H5 (Asian Lineage) influenza viruses in humans, as accessed 02 Oct 2009 at http://www.accessdata.fda.gov/cdrh_docs/pdf8/
k080570.pdf.
In characterizations of analytical sensitivity of this test panel, the CDC has reported analytical LoD in terms of egg culture infectivity titers (EID50/ml). The Department of
Defense Joint Biological Agent Identification & Diagnostic System (JBAIDS) has implemented the same RT-PCR test and reported LoD in TCID50 units of cell culture
infectivity, as accessed 02 Oct 2009 at http://www.fda.gov/downloads/MedicalDevices/Safety/EmergencySituations/UCM180067.pdf.
We estimate CDC rRT-PCR LoD results shown in Table 7 using TCID50 units based on the results of both CDC and JBAIDS for A/Hawaii/15/2001(H1N1).
doi:10.1371/journal.pone.0008995.t007
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subtype, not even testing for the NA component, the assay result is
only based on a pattern of signals from a small panel of RT-PCR
primer-probes.
Some RT-PCR protocols require serial analysis with hierarchi-
cal panels of primer-probes in order to expand the practical
multiplicity of pathogen targets or variants. This is the case with
the benchmark PCR testing used in this report –a type A influenza
virus-positive specimen may be identified in a first round RT-PCR
panel, followed by testing with another panel to distinguish A/H1
from A/H3. Failure to establish subtype A/H1 or A/H3 in the
follow-on test is a first tier screening results for possible
identification of the 2009 Novel A/H1N1 influenza virus outbreak
strain. According to the FACT SHEET FOR HEALTHCARE
PROVIDERS: INTERPRETING CDC HUMAN INFLUENZA
VIRUS REAL-TIME RT-PCR DETECTION AND CHARACTER-
IZATION PANEL FOR RESPIRATORY SPECIMENS (NPS, NS, TS,
NPS/TS, NA1) AND VIRAL CULTURE TEST RESULTS (Autho-
rized by FDA 02 May 2009),
‘‘The rRT-PCR Flu Panel (NPS, NS, TS, NPS/TS, NA)
should be ordered to diagnose influenza A infections caused
by influenza A or B and subtype determination of seasonal
human influenza A virus (seasonal A/H1 or A/H3) to be
used as a first tier test for the in vitro qualitative detection of
novel influenza A (H1N1) virus in patients suspected of
having novel influenza A (H1N1) infection. If the test result
is positive for influenza A and negative for seasonal H1 and
H3 subtypes, the laboratory should test the specimen with
the Swine Influenza Real-time RT-PCR Detection Panel
(rRT-PCR Swine Flu Panel) for the presumptive detection
of novel influenza A (H1N1) infection.’’
It is not at all clear that such hierarchical RT-PCR protocols,
attempting to increase analytical multiplicity through serial testing
of the same specimen(s) at different laboratory venues over a
period likely longer than a single day can be either efficient or cost-
effective. Far more diagnostic intelligence about the patient and
specimen would be available in first-day same-day results from a
single RPM-Flu test of the original specimen.
Utility
Influenza infections do not necessarily preclude co-infection of
the same individual by other viral and/or bacterial pathogens
(including other strains of influenza virus). Such co-infections may
confound a simple diagnosis of influenza, and may also compound
morbidity and mortality for a co-infected patient. However it is not
common practice that a positive result from a routine diagnostic
influenza test would be followed by a call for one or more tests of
possible secondary agents of infection. The single specimen single
aliquot RPM-Flu assay simultaneously targets 30 different
categories of viruses and bacteria, and these were each selected
as a respiratory pathogens reported to cause ‘‘flu-like’’ symptoms
at some stage of human infection.
Implementation of a highly multiplexed differential diagnostic
assay as RPM-Flu would be of great advantage in anticipation of
highly likely future influenza outbreaks, epidemics and pandemics.
For many decades, leaders in the area of influenza epidemic and
pandemic risk assessment and outbreak management have
reviewed the pathology of influenza with respect to rapid
deterioration and patient deaths attributable to secondary
bacterial infections and pneumonia [23,24].
It has taken almost twenty-five years from the first research
reports of the polymerase chain reaction [25] until recent
regulatory clearances have enabled introduction specific PCR-
and RT-PCR-based diagnostic assays and instrumentation into
clinical practice. Such a traditional regulatory clearance timeline
may assure safety and efficacy of diagnostic devices beyond
imaginable limits of liability, but it also assures that best practice
standards for clinical diagnostics are constrained to technologies
that perform with nearly obsolete capabilities and specifications.
Within the last decade resequencing microarrays have been
introduced for research applications and clinical research
[26,27,28]. It would be disappointing to anticipate that another
decade or more may pass before benefits from diagnostic
implementations of RPM or other highly multiplexed sequenc-
ing-based platforms can be realized in routine clinical diagnostics.
Supporting Information
Table S1 Analysis of 2009–2010 FluMist live virus trivalent
vaccine as comparisons of Influenza type A and type B detector tile
sequences to detection and identification of RPM-Flu assay-
generated gene sequences. The strains configured in this vacci-
ne are A/South Dakota/06/2007(H1N1), A/Uruguay/716/2007
(H3N2) and B/Brisbane/60/2008. The vaccine matrix genes and
other non-HA, non-NA genes are from master donor strains A/
Ann Arbor/6/1960(H2N2) and B/Ann Arbor/1/66.
Found at: doi:10.1371/journal.pone.0008995.s001 (0.06 MB
DOC)
Table S2 Analysis of 2009–2010 Fluvirin inactivated virus
trivalent vaccine as comparisons of Influenza type A and type B
detector tile sequences to detection and identification of RPM-Flu
assay-generated gene sequences. The strains configured in this
vaccine are A/Brisbane/59/2007, IVR-148 (H1N1), A/Uruguay/
716/2007(H3N2) and B/Brisbane/60/2008. The type A virus
subtypes of the inactivated vaccines have matrix genes and other
non-HA, non-NA genes derived from the master donor strain A/
Puerto Rico/8/1934 (H1N1).
Found at: doi:10.1371/journal.pone.0008995.s002 (0.07 MB
DOC)
Table S3 Analysis of 2005–2006 inactivated virus trivalent
vaccine as comparisons of Influenza type A and type B detector
tile sequences to detection and identification of RPM-Flu assay-
generated gene sequences. The strains configured inthis vaccine are
A/New Caledonia/20/99 (H1N1), A/New York/55/2004(H3N2)
and B/Jiangsu/10/2003. The type A virus subtypes of the
inactivated vaccines have matrix genes and other non-HA, non-
NA genes derived from the master donor strain A/Puerto Rico/8/
1934 (H1N1). RPM-Flu detector title prototypesequencesC3 Score
BLAST E-value SNPsa Most similar sequence records from
BLAST/GenBank include: Hemagglutinin genes A/New Calde-
donia/20/1999 (H1N1) 62.3 1e-180 4/934 A/New Caldedonia/
20/1999 A/Canterbury/125/2005 (H3N2) 84.6 1e-180 11/1269
A/NewYork/55/2004B/Malaysia/2506/2004 25.22e-8923/226
B/Jilin/20/2003 b B/Shanghai/361/2002 55.8 1e-180 20/502 B/
Jiangsu/10/2003 b Neuraminidase genes A/New Caldedonia/20/
1999 (H1N1) 51.6 1e-180 5/619 A/New Caldedonia/20/1999 A/
Canterbury/125/2005 (H3N2) 89.8 1e-180 2/1077 A/New York/
55/2004 B/Malaysia/2506/2004 55.2 1e-180 21/662 B/Jiangsu/
10/2003 Matrix genes A/Canterbury/100/2000 (H1N1) 54.1 1e-
180 24/459 A/Puerto Rico/8/1934(H1N1) A/Canterbury/125/
2005 (H3N2) 52.4 1e-180 29/445 A/Puerto Rico/8/1934(H1N1)
B/Memphis/13/2003 91.6 1e-180 14/870 B/Jiangsu/10/2003 a
SNPs are single base call discrepancies between detector tile
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The number of detected SNPs is shown relative to the number of
bases called from the detector tile as contiguous runs of three or
more base calls. b The B/Jilin/20/2003 and B/Jiangsu/10/2003
strains are equivalent B/Shanghai/361/2002-like strains as also
used in 2004–2005 vaccine configurations (see Table 1).
Found at: doi:10.1371/journal.pone.0008995.s003 (0.06 MB
DOC)
Table S4 Analysis of 2006–2007 inactivated virus trivalent
vaccine as comparisons of Influenza type A and type B detector tile
sequences to detection and identification of RPM-Flu assay-
generated gene sequences. The strains configured in this vaccine
are A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/
2005(H3N2) and B/Malaysia/2506/2004. The type A virus
subtypes of the inactivated vaccines have matrix genes and other
non-HA, non-NA genes derived from the master donor strain A/
Puerto Rico/8/1934 (H1N1).
Found at: doi:10.1371/journal.pone.0008995.s004 (0.06 MB
DOC)
Table S5 RPM-Flu assay detection and identification of avian
influenza viruses in field and clinical specimens obtained from
human and avian hosts.
Found at: doi:10.1371/journal.pone.0008995.s005 (0.11 MB
DOC)
Table S6 The A/HN subtypes associated with most similar
sequence records for RPM-Flu assay-generated M gene sequences
from 19 type A avian influenza viruses are not reliable indicators
of the actual A/HN subtype. Forty of 79 (51%) most similar M
gene sequence records are associated with different A/HN
subtypes than independently determined from each specimen’s
specific HA and NA gene sequences (mismatches for 8 of 19
specimens).
Found at: doi:10.1371/journal.pone.0008995.s006 (0.07 MB
DOC)
Table S7 The A/HN subtypes associated with most similar
sequence records for RPM-Flu assay-generated NS gene sequenc-
es from 19 type A avian influenza viruses are not reliable
indicators of the actual A/HN subtype. Forty-one of 63 (65%)
most similar NS gene sequence records are associated with
different A/HN subtypes than independently determined from
each specimen’s specific HA and NA gene sequences (mismatches
for 11 of 19 specimens).
Found at: doi:10.1371/journal.pone.0008995.s007 (0.07 MB
DOC)
Table S8 The A/HN subtypes associated with most similar
sequence records for RPM-Flu assay-generated PB2 gene
sequences from 19 type A avian influenza viruses are not reliable
indicators of the actual A/HN subtype. Twenty-two of 58 (38%)
most similar PB2 gene sequence records are associated with
different A/HN subtypes than independently determined from
each specimen’s specific HA and NA gene sequences (mismatches
for 12 of 19 specimens).
Found at: doi:10.1371/journal.pone.0008995.s008 (0.07 MB
DOC)
Figure S1 All combinatorial subtypes of type A influenza virus
strains and 30 different viral and bacterial pathogens causing
influenza-like illness as represented on the RPM-Flu 3.1
resequencing pathogen microarray.
Found at: doi:10.1371/journal.pone.0008995.s009 (0.49 MB TIF)
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